Evolution of Accreditation: How APEx has Evolved to Adopt New Indications

As complexity of radiation therapy increases, ensuring that health care institutions meet rigorous quality standards becomes paramount. Accrediting programs have become a critical instrument for medical practices to achieve comprehensive external assessments and demonstrate their commitment to quality of care. To provide accurate and relevant practice evaluation, accrediting bodies need to adopt new treatment modalities and new indications as they become clinical standards. Radiopharmaceutical therapy (RPT) is a growing, dynamic field in oncology, offering targeted treatments for various cancers, including prostate, thyroid, and neuroendocrine tumors. As the use of radiopharmaceuticals in clinical practice expands, the need for addressing this new modality through accreditation becomes critically important. This activity provides a comprehensive overview of the changes to the accrediting space to accommodate radiopharmaceutical therapy assessments. Focusing on the APEx radiopharmaceutical therapy accreditation process, the activity highlights the role of accreditation in enhancing patient safety, improving treatment efficacy, and fostering interdisciplinary collaboration across specialties. Learners gain insight into the specific requirements for obtaining accreditation and the benefits for clinical practice. 

Topics:

  1. Introduction to APEx and Accreditation
    How Accrediting Bodies have Incorporated New Indications
    Yuliya Lyatskaya, PhD, DABR
  2. The History of RPT and the Creation of RPT Accreditation
    Senthamizhchelvan Srinivasan, PhD
  3. Tips to Success: How to Tackle RPT Evidence Indicators
    Baozhou Sun, PhD, MBA
  4. Q and A
    Yuliya Lyatskaya, PhD, DABR – Moderator
    Full Panel

This activity is available from September 1, 2026, through 11:59 p.m. Eastern time on August 31, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, physicists, nurses, radiation therapists and radiation dosimetrists. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the benefits of accreditation, including improved patient safety, standardized practices and enhanced treatment quality. 
  • Discover the process for maintaining accreditation and the continuous quality improvement practices when new treatment modalities are introduced in clinic with a concentration on radiopharmaceutical therapy.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
09/01/2026
Course expires: 
08/31/2028
Cost:
$149.00
Rating: 
0

Moderator:  

  • Yuliya Lyatskaya, PhD, DABR, is employed by Emory School of Medicine. Dr. Lyatskaya has no relevant financial relationship with ineligible companies to disclose.

Speakers:

  • Senthamizhchelvan Srinivasan, PhD, is employed by Memorial Cancer Center, Indiana University Health. Dr. Srinivasan has no relevant financial relationship with ineligible companies to disclose. 
  • Baozhou Sun, PhD, MBA, is employed by Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine. Dr. Sun has no relevant financial relationship with ineligible companies to disclose.

Planners:

  • Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 
     

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until August 31, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.